Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678639 | 0.78 | MEN1 (0.35) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL14919898 | 0.76 | HTT (0.37) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL21224318 | 0.76 | MEN1 (0.34) | MEN1MAPTKMT2A | |
| SCHEMBL24146618 | 0.76 | KDM4E (0.46) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL26672054 | 0.73 | NPC1 (0.33) | KDM4E | |
| SCHEMBL78004 | 0.72 | — | — | |
| SCHEMBL24146519 | 0.71 | ALDH1A1 (0.33) | MEN1MAPTKMT2A | |
| SCHEMBL1001008 | 0.71 | MEN1 (0.43) | KDM4EMEN1MAPTKMT2ACSNK2A1 | |
| SCHEMBL3567344 | 0.70 | — | — | |
| SCHEMBL791036 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-1646629-B1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100105702-A1 | Heterocyclylethylamide derivatives | BAYER CROPSCIENCE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090093490-A1 | HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1888535-B1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-11-19 | — | — | EP | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1646629-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
| WO-2005005398-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | KDM4E 3396/4885MEN1 4037/4885MAPT 3578/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | KDM4E 4286/4885MEN1 306/4885MAPT 4617/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | KDM4E 3396/4885MEN1 4037/4885MAPT 3578/4885 |
| US-20090093490-A1 | HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | CYP1A2, CYP51A1, CYP1B1 | KDM4E 1506/4885MEN1 634/4885MAPT 2385/4885 |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | KDM4E 3048/4885MEN1 1353/4885MAPT 4302/4885 |
| US-20100105702-A1 | Heterocyclylethylamide derivatives | CYP1A2, CYP3A7, CYP51A1 | KDM4E 1682/4885MEN1 515/4885MAPT 2287/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | KDM4E 4387/4885MEN1 326/4885MAPT 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.